Delayed-onset vemurafenib-induced panniculitis
نویسندگان
چکیده
INTRODUCTION Approved in 2011, vemurafenib is a selective serine/threonine kinase inhibitor directed against the V600E mutation in the BRAF gene. This drug is often used in dermatology as a targeted therapy for metastatic or unresectable melanomas, for which about 50% have this mutation. Other tumors possessing the V600E mutation are targets for this therapy. The commonly reported adverse effects of vemurafenib include rash, squamoproliferative growths, photosensitivity, squamous cell carcinoma, milia, hand-foot skin reaction, and dry skin. Panniculitis is a rare adverse effect associated with BRAF inhibitors. To the authors’ knowledge, this is the first report of histopathologically confirmed delayed-onset vemurafenib-induced panniculitis in an adult, with the patient presenting 324 days after initiating therapy.
منابع مشابه
Panniculitis Associated with MEK Inhibitor Therapy: An Uncommon Adverse Effect
The combination of MEK inhibitor (cobimetinib, trametinib) and BRAF inhibitor (vemurafenib, dabrafenib) is now the first-line treatment in patients with BRAF V600-mutated metastatic melanoma. This association reduces cutaneous adverse events induced by BRAF inhibitors alone, including photosensitivity, hand-foot syndrome, hyperkeratosis, alopecia, skin papillomas, keratoacanthomas, and squamous...
متن کاملCold panniculitis: delayed onset in an adult.
The panniculitides are a complex dermatologic entity for both dermatologists and dermatopathologists. Panniculitis is an inflammation of the subcutaneous adipose tissue and can be associated with systemic diseases. We present a case of cold panniculitis, a form of traumatic panniculitis, in a 37-year-old woman that was caused by a cold therapy unit. Our patient did not develop lesions until 10 ...
متن کاملVemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells.
The V600E mutation in the kinase BRAF is frequently detected in melanomas and results in constitutive activation of BRAF, which then promotes cell proliferation by the mitogen-activated protein kinase signaling pathway. Although the BRAFV600E kinase inhibitor vemurafenib has remarkable antitumor activity in patients with BRAFV600E-mutated melanoma, its effects are limited by the onset of drug r...
متن کاملWeber-Christian panniculitis and auto-immune disease: a case report.
A case is described of Weber-Christian panniculitis accompanied by a gammaglobulin disturbance which preceded by five years the diagnosis of an autoimmune hepatitis and pancytopenia. Also associated was the onset of diabetes mellitus, found at necropsy to be related to pancreatic islet amyloid deposition. This case reinforces the view that Weber-Christian panniculitis may be an adipose response...
متن کاملVemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma
The discovery of BRAF mutations in the majority of patients with metastatic melanoma combined with the identification of highly selective BRAF inhibitors have revolutionized the treatment of patients with metastatic melanoma. The first highly specific BRAF inhibitor, vemurafenib, began clinical testing in 2008 and moved towards a rapid approval in 2011. Vemurafenib induced responses in ~50% of ...
متن کامل